[go: up one dir, main page]

PE20030039A1 - Derivados de indol con afinidad por el receptor 5-ht6 - Google Patents

Derivados de indol con afinidad por el receptor 5-ht6

Info

Publication number
PE20030039A1
PE20030039A1 PE2002000481A PE2002000481A PE20030039A1 PE 20030039 A1 PE20030039 A1 PE 20030039A1 PE 2002000481 A PE2002000481 A PE 2002000481A PE 2002000481 A PE2002000481 A PE 2002000481A PE 20030039 A1 PE20030039 A1 PE 20030039A1
Authority
PE
Peru
Prior art keywords
alkyl
indol
benzenosulfonil
thioalkyl
piperazin
Prior art date
Application number
PE2002000481A
Other languages
English (en)
Inventor
Colin Charles Beard
Robin Douglas Clark
Lawrence Emerson Fisher
Ralph New Harris Iii
David Bruce Repke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20030039A1 publication Critical patent/PE20030039A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A DERIVADOS DE INDOL DE FORMULA I DONDE R1 ES SO(0-2)-A, COA, (CH2)(0-1)-A; A ES ARILO, HETEROARILO OPCIONALMENTE SUSTITUIDO CON HIDROXILO, CIANO, ALQUILO, ALCOXILO, TIOALQUILO, ENTRE OTROS; R2 ES H, ALQUILO C1-C6, ALCOXILO C1-C6, TIOALQUILO C1-C6; R3 ES H, ALQUILO C1-C6, R4 ES H, HALOGENO, ALQUILO C1-C6, ALCOXILO C1-C6, TIOALQUILO C1-C6, HALOALQUILO, CIANO, ALQUILCARBONILO; UNO DE R5, R6, R7 ES UN GRUPO b; W ES CH, N; R8, R9, R10 SON H, ALQUILO C1-C10; R8 Y R9 SON ALQUILENO C3-C4. SON COMPUESTOS PREFERIDOS 3-BENCENOSULFONIL-7-PIPERAZIN-1-IL-1H-INDOL, 3-BENCENOSULFONIL-5-PIPERAIN-1-IL-1H-INDOL, 3-BENCENOSULFONIL-7-PIPERIDIN-4-IL-1H-INDOL, 3-BENCENOSULFONIL-1-METIL-7-PIPERAZIN-1-IL-1H-INDOL, 3-BENCENOSULFONIL-7-(4-METIL-PIPERAZIN-1-IL)-1H-INDOL, ENTRE OTROS. LOS COMPUESTOS TIENEN AFINIDAD POR EL RECEPTOR 5-HIDROXITRIPTAMINA 5-HT6 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE PARKINSON, ANSIEDAD, DEPRESION, PSICOSIS, EPILEPSIA, MIGRANA, TRASTORNO DEL SUENO
PE2002000481A 2001-06-07 2002-06-07 Derivados de indol con afinidad por el receptor 5-ht6 PE20030039A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29670501P 2001-06-07 2001-06-07
US34021201P 2001-12-13 2001-12-13

Publications (1)

Publication Number Publication Date
PE20030039A1 true PE20030039A1 (es) 2003-02-13

Family

ID=26969776

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000481A PE20030039A1 (es) 2001-06-07 2002-06-07 Derivados de indol con afinidad por el receptor 5-ht6

Country Status (32)

Country Link
US (3) US6787535B2 (es)
EP (1) EP1401813B1 (es)
JP (1) JP4187642B2 (es)
KR (1) KR100600240B1 (es)
CN (1) CN1257892C (es)
AR (1) AR036233A1 (es)
AT (1) ATE353318T1 (es)
AU (1) AU2002310747B2 (es)
BG (1) BG108420A (es)
BR (1) BR0210929A (es)
CA (1) CA2449874C (es)
CO (1) CO5630036A2 (es)
CZ (1) CZ20033529A3 (es)
DE (1) DE60218037T2 (es)
ES (1) ES2280546T3 (es)
HR (1) HRP20030984A2 (es)
HU (1) HUP0401307A2 (es)
IL (1) IL158997A0 (es)
MA (1) MA27032A1 (es)
MX (1) MXPA03011244A (es)
NO (1) NO20035359D0 (es)
NZ (1) NZ529631A (es)
PA (1) PA8546601A1 (es)
PE (1) PE20030039A1 (es)
PL (1) PL367305A1 (es)
RU (1) RU2294932C2 (es)
SK (1) SK16052003A3 (es)
TW (1) TW591015B (es)
UY (1) UY27322A1 (es)
WO (1) WO2002098857A1 (es)
YU (1) YU96103A (es)
ZA (1) ZA200309005B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011083A (es) 2001-06-11 2004-07-08 Biovitrum Ab Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii.
US20040242589A1 (en) * 2001-08-07 2004-12-02 Bromidge Steven Mark 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
EP1897881A3 (en) * 2002-06-20 2009-03-18 Biovitrum AB (publ) Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
NZ552282A (en) * 2002-06-20 2008-07-31 Biovitrum Ab Publ New compounds useful for the treatment of obesity, type II diabetes and CNS disorders
CN1314669C (zh) 2002-09-17 2007-05-09 弗·哈夫曼-拉罗切有限公司 2,7－取代的吲哚以及它们作为5－ht6调节剂的用途
AU2004213375A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands
AU2004226838B8 (en) 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
MXPA06000795A (es) 2003-07-22 2006-08-23 Arena Pharm Inc Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo.
BRPI0417833A (pt) * 2003-12-19 2007-04-17 Biovitrum Ab novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
JP2007515429A (ja) * 2003-12-19 2007-06-14 エリクシアー ファーマシューティカルズ， インコーポレイテッド 障害を治療する方法
DK1701940T3 (da) 2003-12-23 2008-09-08 Lundbeck & Co As H 2-(1H-indolylsulfanyl)-bensylaminderivater som SSRI
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
AR050253A1 (es) * 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1799306B1 (en) * 2004-09-30 2011-02-23 F. Hoffmann-La Roche AG Compositions and methods for treating cognitive disorders
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
JP5146766B2 (ja) * 2005-08-15 2013-02-20 ワイス・エルエルシー ５−ヒドロキシトリプタミン−６リガンドとしての置換−３−スルホニルインダゾール誘導体
ES2274725B1 (es) * 2005-11-08 2008-04-01 Laboratorios Del Dr. Esteve, S.A. Indeno derivados, su preparacion y su uso como medicamentos.
CN101370775A (zh) * 2006-01-13 2009-02-18 惠氏公司 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚
EP1984351A1 (en) * 2006-02-17 2008-10-29 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
CA2668959A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
KR101103023B1 (ko) 2007-01-08 2012-01-05 수벤 라이프 사이언시스 리미티드 ５­（헤테로시클릴）알킬­ｎ­（아릴술포닐）인돌 화합물 및 ５­ｈｔ６ 리간드로서 이들의 용도
JP2010515673A (ja) * 2007-01-08 2010-05-13 スベン ライフ サイエンシズ リミティド ４−（ヘテロシクリル）アルキル−ｎ−（アリールスルホニル）インドール化合物および５−ｈｔ６リガンドとしてのその使用
JP2010519226A (ja) * 2007-02-16 2010-06-03 メモリー・ファーマシューティカルズ・コーポレイション ５−ｈｔ６受容体親和性を有する６’位置換インドール及びインダゾール誘導体
WO2008113818A1 (en) * 2007-03-21 2008-09-25 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
KR101162482B1 (ko) 2007-05-03 2012-07-03 수벤 라이프 사이언시스 리미티드 아미노알콕시 아릴술폰아미드 화합물 및 ５-ｈｔ６ 리간드로서의 그의 용도
CA2687132A1 (en) * 2007-05-24 2008-12-04 Memory Pharmaceuticals Corporation 4' substituted compounds having 5-ht6 receptor affinity
CN101801194A (zh) * 2007-08-15 2010-08-11 记忆医药公司 具有5-ht6受体亲和力的3’取代的化合物
US7964627B2 (en) 2007-10-26 2011-06-21 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-HT6 ligands
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
BRPI0908807A2 (pt) * 2008-02-15 2015-07-28 Hoffmann La Roche Derivados de 3-alquil-piperazina e usos dos mesmos
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
BRPI0913736A2 (pt) 2008-09-17 2023-04-11 Suven Life Sciences Ltd Composto, processo para a preparação do composto, composição farmacêutica e método para o tratamento de uma desordem do sistema nervoso central
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
ES2552463T3 (es) 2010-01-05 2015-11-30 Suven Life Sciences Limited Compuestos aromáticos de sulfona útiles para el tratamiento de enfermedades del sistema nervioso central
JP2013536200A (ja) 2010-08-20 2013-09-19 アミラ ファーマシューティカルス，インコーポレーテッド オートタキシン阻害剤およびその使用
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
CN102924359B (zh) * 2012-10-30 2015-03-11 中国科学院烟台海岸带研究所 一种一锅法合成取代吲哚类化合物的方法
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
MX388281B (es) 2015-06-12 2025-03-11 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamiento de un trastorno conductual del sueño rem.
HK1247555A1 (zh) 2015-07-15 2018-09-28 Axovant Sciences Gmbh 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0619805B1 (en) * 1991-11-25 2000-03-15 Pfizer Inc. 5-(hetero- or carbocyclylamino)-indole derivatives, their preparation and their use as 5-ht1 agonists
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
GB9517559D0 (en) * 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
CA2288662A1 (en) * 1997-04-18 1998-11-12 Smithkline Beecham P.L.C. Indole derivatives having combined 5ht1a, 5ht1b and 5ht1d receptor antagonist activity
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
WO2000063203A1 (en) * 1999-04-21 2000-10-26 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-ht6 affinity
AU1542201A (en) * 1999-11-05 2001-05-14 Nps Allelix Corp. Compounds having 5-HT6 receptor antagonist activity
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
PL213134B1 (pl) * 2000-11-02 2013-01-31 Wyeth Corp 1-arylo- lub 1-alkilosulfonylo- heterocyklilobenzazole, ich zastosowanie oraz kompozycja farmaceutyczna zawierajaca te zwiazki
DK1355904T3 (da) * 2000-12-22 2007-10-15 Wyeth Corp Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander
IL156518A0 (en) * 2000-12-22 2004-01-04 Wyeth Corp Heteocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
AR035235A1 (es) * 2001-04-20 2004-05-05 Wyeth Corp Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento
US20040242589A1 (en) * 2001-08-07 2004-12-02 Bromidge Steven Mark 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
WO2004035047A1 (en) * 2002-10-18 2004-04-29 F. Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity

Also Published As

Publication number Publication date
CZ20033529A3 (cs) 2004-04-14
HK1068610A1 (en) 2005-04-29
MA27032A1 (fr) 2004-12-20
EP1401813B1 (en) 2007-02-07
PA8546601A1 (es) 2003-01-24
RU2003136731A (ru) 2005-05-20
DE60218037T2 (de) 2007-08-23
KR20040004702A (ko) 2004-01-13
WO2002098857A8 (en) 2004-04-22
CA2449874A1 (en) 2002-12-12
NZ529631A (en) 2006-08-31
KR100600240B1 (ko) 2006-07-13
US6787535B2 (en) 2004-09-07
US20050171118A1 (en) 2005-08-04
TW591015B (en) 2004-06-11
JP4187642B2 (ja) 2008-11-26
RU2294932C2 (ru) 2007-03-10
BG108420A (en) 2005-02-28
YU96103A (sh) 2006-08-17
ATE353318T1 (de) 2007-02-15
BR0210929A (pt) 2004-06-08
NO20035359D0 (no) 2003-12-02
US20030073700A1 (en) 2003-04-17
US20040248902A1 (en) 2004-12-09
WO2002098857A1 (en) 2002-12-12
HUP0401307A2 (hu) 2004-12-28
IL158997A0 (en) 2004-05-12
ZA200309005B (en) 2005-02-21
ES2280546T3 (es) 2007-09-16
UY27322A1 (es) 2003-02-28
CA2449874C (en) 2009-06-23
CO5630036A2 (es) 2006-04-28
CN1257892C (zh) 2006-05-31
DE60218037D1 (de) 2007-03-22
PL367305A1 (en) 2005-02-21
EP1401813A1 (en) 2004-03-31
CN1527816A (zh) 2004-09-08
AR036233A1 (es) 2004-08-25
AU2002310747B2 (en) 2007-10-11
JP2004533460A (ja) 2004-11-04
HRP20030984A2 (en) 2005-10-31
SK16052003A3 (en) 2004-10-05
MXPA03011244A (es) 2004-02-27

Similar Documents

Publication Publication Date Title
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
PE20220597A1 (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20040935A1 (es) Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20080067A1 (es) DERIVADOS DE TRIAZOLOPIRAZINA COMO MODULADORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (c-MET O HGFR)
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
PE20060626A1 (es) Aminas policiclicas sustituidas con arilo como antagonistas de mch1r
PE20030119A1 (es) Derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6
PE20040590A1 (es) Composiciones de pirrolotriazina anilina como inhibidores de cinasa
PE20010574A1 (es) Derivados de indol como ligandos del receptor 5-ht2
AR040349A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
PE41796A1 (es) Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c.
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20070181A1 (es) DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA
PE20010641A1 (es) Derivados de piperazina como antagonistas del receptor de serotonina 5-ht1b
PE20060604A1 (es) Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion
PE20040828A1 (es) Benzoxazinonas como modulares de 5-hidroxitriptamina (5-ht)
AR030913A1 (es) Un compuesto derivado de indolina, su uso, un procedimiento para prepararlo, una composicion farmaceutica que lo comprende y un procedimiento para preparar dicha composicion

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed